Salute e Benessere

AB Science announces the successful completion of a 2.55 million euros private…

PRESS RELEASEAB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.55 MILLION PRIVATE PLACEMENTParis, August 4, 2025, 8am CET AB Science S.A. (the “ Company ” or “ AB Science ”, Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 2.55 million subscribed by a limited number of investors (the “ Private Placement ”).The Private Placement is not subject to a prospectus requiring an approval from the French...

CAS SciFinder integrates transformative new science-smart AI capabilities to…

This marks the most significant integration of AI within the CAS solution portfolio to date. "Scientific information is diverse and complex, making it challenging for common AI tools to interpret accurately," noted Tim Wahlberg, CAS Chief Product Officer. "Applying these technologies to the high-quality, structured data in the CAS Content Collection™ and engaging our team of scientists to verify the advanced AI models enabled us to develop a science-smart AI approach that delivers…

Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance…

Through this collaboration, Shilpa Biologics, the biologics arm of Shilpa Medicare, will become Alveolus Bio's exclusive global development and manufacturing partner. This partnership propels Alveolus Bio's live biotherapeutics and small molecule platform towards Phase 2 and first-in-human clinical trials, with a lead asset for COPD progressing rapidly. Through this collaboration,Shilpa Biologics, the biologics arm of Shilpa Medicare, will become Alveolus Bio's exclusive global development...

Financière de Tubize - 2025 half-year financial report

Half-year financial report 2025 Regulated information 2 August 2025The board of directors of Financière de Tubize has established the 2025 half-year report. This report is available on the websitewww.financiere-tubize.be. Profit for the first half of 2025: € 95.6 million (€ 92.9 million in 2024, + 2.8%),Dividend received from UCB: € 98.1 million (€ 1.39 per share, an increase of 2.2% compared to the previous year),2024 Dividend paid to Financière de Tubize’s shareholders in 2025 of...

Information regarding the total number of voting rights and total number of…

Informationregardingthetotalnumberofvotingrightsand total number of shares of the Company as of July 31, 2025 (Article 223-16 of the General Regulations of theAutoritédesMarchésFinanciers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 DateTotalnumberofsharesTotalnumberofvotingrights 07/31/2025 136,975,159 Total gross of voting rights: 136,975,159Total net* of voting rights:...

Roche’s Susvimo maintains vision over five years with two refills per year in…

Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in nAMD, the leading cause of vision loss in people over the age of 60With two refills per year, Susvimo maintained vision and stabilised the retina for five years, with durability maintained in approximately 95% of patientsSusvimo was well tolerated over five years and has a well-characterised safety profile Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today...

Casino Group: Release of the half year 2025 Financial Report

RELEASE OF THE HALF YEAR 2025FINANCIAL REPORT The Group has released its half year 2025 financial report, in English, on its website. It is available following this link: https://www.groupe-casino.fr/wp-content/uploads/2025/08/20250801-H1-2025-Financial-Report.pdf Analyst and investor contactsCharlotte Izabel +33 (0)6 89 19 88 33 [email protected] Relations +33 (0)1 53 65 24 [email protected] Press contacts...

Surgical Sutures Market Worth US$6.65 billion by 2030 with 6.5% CAGR |…

Browse in-depth TOC on "Surgical Sutures Market"348 - Tables52 - Figures319 - Pages Browse in-depth TOC on "Surgical Sutures Market" 348 - Tables 52 - Figures 319 - Pages By product,Suture thread dominates the surgical sutures market due to its essential role in wound closure across various surgical procedures. As the core component of any suturing system, it is integral to traditional open surgeries and minimally invasive techniques. The preeminence of suture thread can…

Suppositories Market Worth $2.05 billion by 2030 with 4.7% CAGR |…

Browse in-depth TOC on "Suppositories Market" Browse in-depth TOC on "Suppositories Market" 150 - Tables 60 - Figures 350 - Pages By type,the suppositories market is categorized into rectal, vaginal, and urethral, with the rectal segment commanding the largest market share. This predominance is attributed to the broad therapeutic coverage and high patient acceptance by geriatric and pediatric populations. Rectal suppositories are commonly prescribed for pain and fever,...

Oculis Upsized Loan Facility to Access up to CHF 100 million

The Amended Loan Agreement replaces the prior loan agreement between Oculis and the Lender dated May 29, 2024, and the upsized structure will provide CHF 75.0 million in borrowing capacity (which may be increased to up to CHF 100.0 million) (the “Loan”). The Loan comprises tranches 1, 2 and 3, in the amounts of CHF 25.0 million each, as well as an additional loan of up to CHF 25.0 million, which may be made available by the Lender to Oculis on mutually agreed terms. No amounts were drawn...

Medit to Reveal New Medit i900 Mobility, Powered by True Mobility

The i900 Mobility transforms how clinicians work, move and connect with patients by combining precision with ease of use. At the core of this experience is Medit Link Express, the company's first iPad-native companion app, designed to simplify scan-and-send workflows through an intuitive, user-friendly interface. With real-time scan viewing and built-in patient engagement, the app transforms the iPad into a seamless bridge between clinician and patient — immediate, effortless and mobile…

SciBase announces outcome in directed share issue

Allotment of shares Allotment of shares Castle Biosciences' undertaking to subscribe for shares in the Directed Issue was conditional upon a notification that the application is left without action or approval of the investment from the ISP, pursuant to the Swedish Screening of Foreign Direct Investment Act (2023:560). ISP has notified that the application is left without action and all shares in the Directed Issue have now been subscribed for. The Board of Directors of SciBase has...

Norgine welcomes PBS listing in Australia of IFINWIL® (eflornithine) for…

Lucy Jones, CEO Neuroblastoma Australia, welcomed the news:"On behalf of all families of children impacted by neuroblastoma, we welcome the PBS listing of IFINWIL ®. We urgently need treatments for children diagnosed with neuroblastoma and this listing ensures every child inAustraliahas equal access to a new therapy for this aggressive and complex cancer. Providing options to new treatments is critical in ensuring every child diagnosed has the best chance of survival...

KIT Inhibitors Market Growth: Key Trends and Future Projections in the 7MM Upto…

Key Takeaways from the KIT Inhibitors Market Report Key Takeaways from the KIT Inhibitors Market Report Discover which indication is expected to grab the major KIT inhibitors market share @KIT Inhibitors Market Report KIT Inhibitors Market Dynamics The KIT inhibitors market is shaped by a combination ofgrowing clinical demand, limited therapeutic options, and ongoing advancementsin targeted therapies. KIT, a receptor tyrosine kinase, plays a crucial role in cell growth...

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Daix (France), New York (New York, United States), July 31, 2025– Inventiva (Euronext Paris and Nasdaq: IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“ MASH ”), also known as non-alcoholic steatohepatitis (“ NASH ”), and other diseases with significant unmet medical needs, today announced the half-year report...

PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the…

PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial FDA agreed that PolTREG’s clinical data in Stage 3 Type 1 Diabetes (T1D) appears sufficient to support the Prospect of Direct benefit in an adaptive Phase 2/3 study of PTG-007 in Stage 1 and Stage 2 Presymptomatic T1D patients. The FDA is receptive to the inclusion of Stage 1 Polish patients in the trial’s statistical analyses FDA may...

Flo Reaches Settlement in Class Action Lawsuit After Judge Said He Would Toss…

The terms of the settlement are subject to final court approval. More information about the settlement, including eligibility and next steps for the US class members, will be available via official court-approved communications in the coming weeks. The terms of the settlement are subject to final court approval. More information about the settlement, including eligibility and next steps for the US class members, will be available via official court-approved communications in the coming weeks...

Availability of 2025 Half-Year Financial Report

Press Release Paris – July 31, 2025 –EUROAPI posted today its 2025 condensed Half-Year Consolidated Financial Statements for the six months ended June 30, 2025. This document is available for consultation and downloading on EUROAPI’s website: https://www.euroapi.com/en/investors/regulatory-information/financial-reports. This report includes notably the 2025 half-year management report, the consolidated financial statements on 30 June 2025, and the Statutory Auditors’...

Press release: Online availability of Sanofi’s half-year financial report for…

Online availability of Sanofi’s half-year financial report for 2025Paris, July 31, 2025. Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K.This document may be found on the company’s corporate website:www.sanofi.comand downloaded from the “Investors”...

Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)

Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025) Attachment 2025 Half-year Financial Report_Ipsen SA

Press release: Use of alfapump® to control ascites enabling elective umbilical…

Use of alfapump® to control ascites enabling elective umbilical hernia repair published inHerniaUntreated umbilical hernias occur in 20% of patients with ascites due to liver cirrhosis. Without treatment, there is a significant risk of complications that are life threatening and require emergency surgeryEffective management of ascites is necessary for elective surgical repair in such patientsThe team at Mayo Clinic, Arizona present a case report of a patient in the...

Pharmaceutical Metal Detectors Market worth US$197.7 million by 2030 with 4.7%…

Browse in-depth TOC on "Pharmaceutical Metal Detectors Market" Browse in-depth TOC on "Pharmaceutical Metal Detectors Market" 400 - Tables 100- Figures 400 - Pages By product type,tablet metal detectors dominated the pharmaceutical metal detectors market in 2024 due to the widespread production of tablets, which are the most commonly used dosage form, owing to their ease of use and long shelf life. Since tablet manufacturing involves multiple mechanical steps, there is a...

MarketsandMarkets' 360Quadrants Recognizes Top Startups and SMEs in the Smart…

Company Highlights in the Smart Pills Startups/SMEs Companies Assessment: Company Highlights in the Smart Pills Startups/SMEs Companies Assessment: To explore the full quadrant report and see how companies are positioned in the Smart Pills Startups/SMEs Companies Assessment, 2025, Visit:https://www.360quadrants.com/healthcare/smart-pills-startups Evaluation Criteria The vendor evaluation was conducted on over 80 companies, of which the top 8 were categorized and recognized...

Contract Research Organization Market is Poised to Reach USD 122.2 Billion by…

Download Sample Pages of the Report: https://www.skyquestt.com/sample-request/contract-research-organization-market Download Sample Pages of the Report:https://www.skyquestt.com/sample-request/contract-research-organization-market Contract Research Organization Market Key Growth Drivers Over the years, pharmaceutical and biotechnology companies have increasingly used CROs in R&D due to their cost-effectiveness and efficiency. This would allow companies to leverage the specialized...

Altri Comunicati